UBS Group
ITCI

UBS Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

UBS Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-53,500
Closed -$7.06M – 11206
2025
Q1 		$7.06M Buy
+53,500
New +$6.67M ﹤0.01% 3430

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

UBS Group's ITCI Position: Q2 2025 in Review

UBS Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,590,345 shares — an estimated $210M sold.

UBS Group first reported a position in ITCI in Q4 2014 and held it in 42 quarters. The position peaked at $210M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • UBS Group reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • UBS Group sold 1,590,345 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $210M.
  • UBS Group first reported a position in Intra-Cellular Therapies Inc. in Q4 2014 and held it in 42 quarters.
  • UBS Group's Intra-Cellular Therapies Inc. position peaked at $210M in Q1 2025.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.